BiotechTube
Home/Spyre Therapeutics/Joshua Friedman
JF

Joshua Friedman

SVP, Clinical Development

Spyre Therapeutics

Therapeutic Areas

GastroenterologyRheumatologyImmunology

Spyre Therapeutics Pipeline

DrugIndicationPhase
SPY001Ulcerative Colitis (UC)Phase 2
SPY002Ulcerative Colitis (UC)Phase 2
SPY003Ulcerative Colitis (UC)Phase 2
SPY120Ulcerative Colitis (UC)Phase 1
SPY130Ulcerative Colitis (UC)Phase 1
SPY230Ulcerative Colitis (UC)Phase 1
SPY072Rheumatoid Arthritis (RA)Phase 2

Leadership Team at Spyre Therapeutics

CT
Cameron Turtle
Chief Executive Officer
SS
Sheldon Sloan
Chief Medical Officer
SB
Scott Burrows
Chief Financial Officer
KT
Kate Tansey Chevlen
Chief Commercial Officer
BC
Brian Connolly
Chief Technical Officer
HK
Heidy King-Jones
Chief Legal Officer and Corporate Secretary
JM
James Myers
SVP, Quality and Compliance
MZ
Matthew Zinder
SVP, Regulatory Affairs
JL
Justin LaFountaine
SVP, Corporate Development
EM
Eric McIntyre
SVP, Finance and Investor Relations
View full Spyre Therapeutics profile